Search Prime Grants

UG1EY028096

Cooperative Agreement

Overview

Grant Description
Adalimumab versus conventional immunosuppression for uveitis (ADVISE) trial.
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Baltimore, Maryland 212052103 United States
Geographic Scope
Single Zip Code
Analysis Notes
Amendment Since initial award the End Date has been extended from 08/31/23 to 08/31/25 and the total obligations have increased 862% from $128,156 to $1,233,041.
The Johns Hopkins University was awarded ADALIMUMAB VERSUS CONVENTIONAL IMMUNOSUPPRESSION FOR UVEITIS (ADVISE) TRIAL Cooperative Agreement UG1EY028096 worth $1,233,041 from National Eye Institute in September 2018 with work to be completed primarily in Baltimore Maryland United States. The grant has a duration of 7 years and was awarded through assistance program 93.867 Vision Research. The Cooperative Agreement was awarded through grant opportunity NEI Clinical Vision Research: Chairman's Grant (UG1).

Status
(Complete)

Last Modified 8/5/24

Period of Performance
9/30/18
Start Date
8/31/25
End Date
100% Complete

Funding Split
$1.2M
Federal Obligation
$0.0
Non-Federal Obligation
$1.2M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to UG1EY028096

Subgrant Awards

Disclosed subgrants for UG1EY028096

Transaction History

Modifications to UG1EY028096

Additional Detail

Award ID FAIN
UG1EY028096
SAI Number
UG1EY028096-2793111504
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Private Institution Of Higher Education
Awarding Office
75NW00 NIH NATIONAL EYE INSTITUTE
Funding Office
75NW00 NIH NATIONAL EYE INSTITUTE
Awardee UEI
FTMTDMBR29C7
Awardee CAGE
5L406
Performance District
MD-07
Senators
Benjamin Cardin
Chris Van Hollen

Budget Funding

Federal Account Budget Subfunction Object Class Total Percentage
National Eye Institute, National Institutes of Health, Health and Human Services (075-0887) Health research and training Grants, subsidies, and contributions (41.0) $1,497,180 100%
Modified: 8/5/24